Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Integra Lifesciences

Integra Lifesciences (NASDAQ: IART) insider transactions

In the twelve months to 10 November 2026, executives and directors of Integra Lifesciences reported no open-market sales and no open-market purchases, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Integra Lifesciences shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
1 September 2026Veillon-Berteloot ChantalEVP & ChroShares withheld for tax−1,455$16.6220,772Form 4
3 July 2026Knight Lea DanielsEVP & Chief Financial OfficerShares withheld for tax−5,226$18.0545,263Form 4
1 July 2026Mosebrook JeffreySVP, Fin & Princ Acct OfficerShares withheld for tax−937$17.8934,516Form 4
9 May 2026Bradley KeithDirectorShares withheld for tax−882$13.9288,254Form 4
7 May 2026Hill Barbara BDirectorGrant or award+6,638—133,491Form 4
7 May 2026Hill Barbara BDirectorGrant or award+17,700—151,191Form 4
11 March 2026Davis Robert T. Jr.EVP & President, TTShares withheld for tax−8,487$9.6166,387Form 4
11 March 2026Mosebrook JeffreySVP, Fin & Princ Acct OfficerShares withheld for tax−806$9.6135,453Form 4
11 March 2026McBreen Michael J.EVP & President, CSSShares withheld for tax−7,247$9.6160,743Form 4
11 March 2026Singh HarvinderEVP & President, InternationalShares withheld for tax−861$9.6121,690Form 4
11 March 2026Singh HarvinderEVP & President, InternationalOption exercise+18,922—40,612Form 4
11 March 2026Singh HarvinderEVP & President, InternationalShares withheld for tax−5,190$9.6135,422Form 4
11 March 2026Knight Lea DanielsEVP & Chief Financial OfficerShares withheld for tax−8,089$9.6150,489Form 4
11 March 2026Veillon-Berteloot ChantalEVP & ChroShares withheld for tax−5,420$9.6122,227Form 4
10 March 2026Davis Robert T. Jr.EVP & President, TTShares withheld for tax−687$9.5574,874Form 4
10 March 2026Mosebrook JeffreySVP, Fin & Princ Acct OfficerShares withheld for tax−341$9.5536,259Form 4
10 March 2026McBreen Michael J.EVP & President, CSSShares withheld for tax−2,354$9.5567,990Form 4
10 March 2026Singh HarvinderEVP & President, InternationalOption exercise+1,216—23,152Form 4
10 March 2026Singh HarvinderEVP & President, InternationalShares withheld for tax−601$9.5522,551Form 4
6 January 2026Poul MojdehPresident & CEOOption exercise+848—848Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Integra Lifesciences page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.